Division of Colon and Rectal Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-Ro 43-Gil, Songpa-Gu, Seoul, 05505, Korea.
Sci Rep. 2022 Sep 1;12(1):14910. doi: 10.1038/s41598-022-19329-8.
The albumin-bilirubin (ALBI) score was created to assess the severity of liver dysfunction and to predict prognosis of hepatocellular carcinoma. Purpose of this study was to investigate the prognostic value of the ALBI score in patients with stage III colon cancer using propensity score matching (PSM) analysis. This study analyzed 510 patients with stage III colon cancer who had surgery between 2014 and 2015. The ALBI score was calculated as follows: (log bilirubin (μmol/L) [Formula: see text] 0.66) + (albumin (g/L) [Formula: see text] -0.0852), and the optimal cut-off value was determined using a receiver operating characteristic analysis and the Youden Index. According to the calculated cut-off value, patients were divided into two groups: Group A (ALBI ≤ - 2.54) and Group B (ALBI > - 2.54). The average ALBI score was - 2.68 (from - 3.39 to - 0.69). Group A had a significantly higher 5-year disease-free survival rate (85.5% vs 75.7%, p = 0.02), 5-year cancer-specific survival rate (93.7% vs 84.4%, p = 0.02), and 5-year overall survival rate (90.6% vs 77.4%, p = 0.01) than Group B. High ALBI scores were found to be an independent risk factor for both disease-free survival (HR 1.68, p = 0.048) and cancer-specific survival (HR 2.24, p = 0.028). The preoperative ALBI score was found to be a promising prognostic indicator for predicting recurrence and survival in patients with stage III colon cancer in this study. Because the ALBI score is simple and inexpensive to obtain, it has the potential to be a useful clinical marker for colon cancer patients.
目的 本研究旨在通过倾向评分匹配（PSM）分析，探讨白蛋白-胆红素（ALBI）评分在 III 期结肠癌患者中的预后价值。
方法 本研究分析了 2014 年至 2015 年间接受手术治疗的 510 例 III 期结肠癌患者。ALBI 评分的计算方法如下：（log 胆红素（μmol/L）[公式：见正文]0.66）+（白蛋白（g/L）[公式：见正文]-0.0852），并使用接受者操作特征分析和 Youden 指数确定最佳截断值。根据计算出的截断值，将患者分为两组：A 组（ALBI≤-2.54）和 B 组（ALBI>-2.54）。平均 ALBI 评分为-2.68（-3.39 至-0.69）。A 组的 5 年无病生存率（85.5%比 75.7%，p=0.02）、5 年癌症特异性生存率（93.7%比 84.4%，p=0.02）和 5 年总生存率（90.6%比 77.4%，p=0.01）均显著高于 B 组。高 ALBI 评分被发现是无病生存（HR 1.68，p=0.048）和癌症特异性生存（HR 2.24，p=0.028）的独立危险因素。本研究发现，术前 ALBI 评分是预测 III 期结肠癌患者复发和生存的有前途的预后指标。由于 ALBI 评分获取简单且价格低廉，因此有可能成为结肠癌患者的有用临床标志物。
